Glaxosmithkline Pharmaceutical Profit & Loss Annual

BSE: 500660 | NSE: GLAXO | ISIN: INE159A01016 | Sector: Biotechnology & Drugs
3,200.00 +6.00 (0.19%)Updated : 20 Jun 2025
Fiscal Period2025202420232022
Period End DateMar 25Mar 24Mar 23Mar 22
Revenue 3,749.213,453.713,251.723,278.03
Total Revenue 3,749.213,453.713,251.723,278.03
Costof Revenue Total 1,512.301,457.101,394.281,482.14
Gross Profit 2,236.911,996.611,857.441,795.89
Selling/ General/ Admin Expenses Total 996.641,026.91991.00981.81
Depreciation/ Amortization 66.6669.5465.6268.04
Interest Exp( Inc) Net- Operating Total 0.130.140.140.14
Other Operating Expenses Total 60.6461.0152.2447.06
Total Operating Expense 2,636.372,778.002,513.912,599.03
Operating Income 1,112.84675.71737.81679.00
Interest Inc( Exp) Net- Non- Op Total 137.58115.0589.2964.87
Gain( Loss)on Saleof Assets 4.6920.589.6731.72
Other Net 4.774.85-0.373.45
Net Income Before Taxes 1,259.88816.19836.40779.05
Provisionfor Income Taxes 332.30226.23228.76398.28
Net Income After Taxes 927.58589.96607.64380.77
Net Income Before Extra Items 927.58589.96607.64380.77
Net Income 927.58589.96610.691,694.72
Income Availableto Com Excl Extra Ord 927.58589.96607.64380.77
Income Availableto Com Incl Extra Ord 927.58589.96610.691,694.72
Diluted Net Income 927.58589.96610.691,694.72
Diluted Weighted Average Shares 16.9416.9416.9416.94
Diluted EPS Excluding Extra Ord Items 54.7634.8335.8722.48
DPS- Common Stock Primary Issue 42.0032.0032.0030.00
Diluted Normalized EPS 54.5540.9235.9122.13
period Length 12.0012.0012.0012.00
period Type ----
Unusual Expense( Income) -163.3010.6119.82
Total Extraordinary Items -0.003.041,313.95
*All figures in crores except per share values
Recommended For You
Trending Stocks
1,936.95+61.35(3.27%)
12,803.60-2.55 (-0.02%)